MRM’s Therapeutic Laser Earns FDA Nod for Fibromyalgia Pain

Multi Radiance Medical (MRM) has achieved U.S. Food and Drug Administration (FDA) clearance for its FibroLux laser to treat fibromyalgia pain. According to the company, it’s the first laser therapy manufacturer to receive this type of FDA clearance.
 
According to the American College of Rheumatology, fibromyalgia is typically treated with prescription drugs but they only provide relief for about 10% of patients using them.
 
The non-pharmacological, non-invasive, and side effect-free FibroLux (patent pending) delivers optimal doses of light energy using a combo of curated wavelengths administered at the correct dose (time and power) and ideal dosage (frequency of application) for consistent, reproducible outcomes.
 
The laser therapy device was found to reduce tender point count, mean pain ratings, and Fibromyalgia Impact Questionnaire scores compared to placebo in a clinical trial. Findings demonstrated FibroLux was safe and effective to reduce fibromyalgia pain with an average three- to six-minute treatment time,
 
According to the company, 59+ peer-reviewed articles have been published about MRM’s technology and MRM has participated in over 35 clinical trials.
 
“Laser therapy has been a game-changer in the rehabilitation and pain management space for years. Now, as the first laser company to achieve a patent and FDA clearance for relief of fibromyalgia pain, this opens the door for how to effectively manage this tough condition,” MRM CEO Max Kanarsky told the press. “We want to thank our research team for their efforts in the clinical trial process as we continue to expand the applications of laser therapy.”